Extrahepatic transarterial radioembolization to treat fibrolamellar hepatocellular carcinoma: A case report

Fibrolamellar hepatocellular carcinoma (FL-HCC) is a rare primary liver tumor that typically presents at an advanced stage in early adolescents and adults with no underlying liver disease. Surgical resection is the first-line treatment, and patients who are not surgical candidates face limited treat...

Full description

Saved in:
Bibliographic Details
Published in:Radiology case reports 2020-12, Vol.15 (12), p.2613-2616
Main Authors: Ljuboja, Damir, Weinstein, Jeffrey L, Ahmed, Muneeb, Sarwar, Ammar
Format: Article
Language:English
Subjects:
Case Report
Extrahepatic
Fibrolamellar hepatocellular carcinoma
TARE
Yttrium-90 radioembolization
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Fibrolamellar hepatocellular carcinoma (FL-HCC) is a rare primary liver tumor that typically presents at an advanced stage in early adolescents and adults with no underlying liver disease. Surgical resection is the first-line treatment, and patients who are not surgical candidates face limited treatment options with poor long-term outcomes. Herein we report the first documented, technically successful treatment of FL-HCC with extrahepatic spread using transarterial radioembolization (TARE) in a 16-year-old male patient with surgically unresectable disease. Subsequent imaging revealed tumor necrosis and a 20% reduction in size, and the patient survived 20 months post-treatment, a marked improvement relative to historical data in the literature. Further research should examine the potential role of yttrium-90 TARE in the treatment of FL-HCC patients with metastatic disease.
ISSN:1930-0433
1930-0433
DOI:10.1016/j.radcr.2020.09.043